RGD Reference Report - Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Disturbed neurotransmitter transporter expression in Alzheimer's disease brain.

Authors: Chen, KH  Reese, EA  Kim, HW  Rapoport, SI  Rao, JS 
Citation: Chen KH, etal., J Alzheimers Dis. 2011;26(4):755-66.
RGD ID: 5686430
Pubmed: PMID:21743130   (View Abstract at PubMed)
PMCID: PMC3188700   (View Article at PubMed Central)
DOI: DOI:10.3233/JAD-2011-110002   (Journal Full-text)

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia. An imbalance of different neurotransmitters--glutamate, acetylcholine, dopamine, and serotonin--has been proposed as the neurobiological basis of behavioral symptoms in AD. The molecular changes associated with neurotransmission imbalance in AD are not clear. We hypothesized that altered reuptake of neurotransmitters by vesicular glutamate transporters (VGLUTs), excitatory amino acid transporters (EAATs), the vesicular acetylcholine transporter (VAChT), the serotonin reuptake transporter (SERT), or the dopamine reuptake transporter (DAT) are involved in the neurotransmission imbalance in AD. We tested this hypothesis by examining protein and mRNA levels of these transporters in postmortem prefrontal cortex from 10 AD patients and 10 matched non-AD controls. Compared with controls, protein and mRNA levels of VGLUTs, EAAT1-3, VAChT, and SERT were reduced significantly in AD. Expression of DAT and catechol O-methyltransferase was unchanged. Reduced VGLUTs and EAATs may contribute to an alteration in glutamatergic recycling, and reduced SERT could exacerbate depressive symptoms in AD. The reduced VAChT expression could contribute to the recognized cholinergic deficit in AD. Altered neurotransmitter transporters could contribute to the pathophysiology of AD and are potential targets for therapy.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
SLC18A3HumanAlzheimer's disease  IEP mRNA and protein:decreased expression:frontal association cortex RGD 
Slc18a3RatAlzheimer's disease  ISOSLC18A3 (Homo sapiens)mRNA and protein:decreased expression:frontal association cortex RGD 
Slc18a3MouseAlzheimer's disease  ISOSLC18A3 (Homo sapiens)mRNA and protein:decreased expression:frontal association cortex RGD 

Objects Annotated

Genes (Rattus norvegicus)
Slc18a3  (solute carrier family 18 member A3)

Genes (Mus musculus)
Slc18a3  (solute carrier family 18 (vesicular monoamine), member 3)

Genes (Homo sapiens)
SLC18A3  (solute carrier family 18 member A3)


Additional Information